- Home
- GNTA vs GANX Comparison
GNTA vs GANX Comparison
Compare GNTA & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | GANX |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.7M | 74.6M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GNTA | GANX |
|---|---|---|
| Price | $1.31 | $2.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 43.3K | ★ 516.1K |
| Earning Date | 03-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $1.53 |
| 52 Week High | $10.00 | $4.34 |
Technical Indicators
Market Signals| Indicator | GNTA | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 41.49 | 61.39 |
| Support Level | $1.28 | $1.64 |
| Resistance Level | $1.70 | $2.22 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 25.00 | 58.45 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon, a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.